Marie-Therese Holzer, Robert Biesen, Sarah Tansley, Carsten Dittmayer, Werner Stenzel, Udo Schneider
<p>With great interest, we read the article on the clinico-sero-pathological characteristics of anti-Ha antisynthetase syndrome by Zhao et al. [<span>1</span>].</p><p>The authors describe 12 patients with anti-Ha as a single myositis-specific antibody [<span>1</span>]. In light of this manuscript, we would like to add a report and discuss an anti-Ha-positive patient (a 39-years-old female), who was diagnosed and treated at the university hospital Charité Berlin with severe antisynthetase syndrome (ASyS).</p><p>The patient initially presented in 2023 with arthralgia and scaly skin on her palms (see Figure 1A) and was diagnosed with psoriatic arthritis. In the following months, she developed a dry cough and myalgia, and subsequently, in early 2024, progressive dyspnoea and night sweats. Because of the existing prednisolone and TNF-inhibitor treatment for supposed psoriatic arthritis, an infection with <i>pneumocystis jirovecii</i> was suspected. Following a thorough and negative infection screen, the patient was ultimately transferred to the intensive care unit of the Charité with acute respiratory distress syndrome (ARDS) and evaluated for possible lung transplantation (see Figure 1D). Because of progressive respiratory insufficiency, high-dose glucocorticosteroids as well as cyclophosphamide were initiated. The suspected diagnosis was revised to idiopathic inflammatory myopathy (IIM) based on the clinical presentation with arthritis, myalgia with elevated creatine kinase (CK, 939 U/L), scaly exanthema (retrospectively identified as mechanic hands) and rapidly progressive interstitial lung disease (RP-ILD). Immunofluorescence on HEp2 cells revealed a speckled cytoplasmic pattern with a titre of 1:640 (see Figure 1B). Despite repetitive testing of myositis-specific and myositis-associated antibodies with commercial line blots, only anti-Ro52 antibodies were identified. Therefore, after muscle MRI showing patchy oedema and fasciitis, a muscle biopsy of the M. quadriceps was performed. This revealed a histopathological pattern consistent with ASyS: A mild but typical pattern of perifascicular necrosis and atrophy, as well as positive MHC class I and II staining with a perifascicular pattern (particularly for MHC class II) (see Figure 2).</p><p>Combined, the clinical symptoms with a complete clinical triad (Arthritis, Myositis, ILD [<span>2, 3</span>]) and the muscle biopsy consistent with ASyS led to the diagnosis of ASyS [<span>4</span>]. Hence, treatment was expanded to include rituximab (RTX), as a good response to RTX in ASyS had been reported [<span>4, 5</span>]. To search thoroughly for possible autoantibodies in this apparent myositis-specific antibody-negative case, radioimmunoprecipitation was performed at the University of Bath [<span>6</span>] and anti-Ha-antibodies were identified (see Figure 1C). Following RTX therapy, the patient experienced significant improvement of her ILD (see early follow-up CT, Figure 1D). On subsequent outpatient
{"title":"Correspondence to: Clinico-sero-pathological characteristics of anti-Ha antisynthetase syndrome","authors":"Marie-Therese Holzer, Robert Biesen, Sarah Tansley, Carsten Dittmayer, Werner Stenzel, Udo Schneider","doi":"10.1111/bpa.70015","DOIUrl":"10.1111/bpa.70015","url":null,"abstract":"<p>With great interest, we read the article on the clinico-sero-pathological characteristics of anti-Ha antisynthetase syndrome by Zhao et al. [<span>1</span>].</p><p>The authors describe 12 patients with anti-Ha as a single myositis-specific antibody [<span>1</span>]. In light of this manuscript, we would like to add a report and discuss an anti-Ha-positive patient (a 39-years-old female), who was diagnosed and treated at the university hospital Charité Berlin with severe antisynthetase syndrome (ASyS).</p><p>The patient initially presented in 2023 with arthralgia and scaly skin on her palms (see Figure 1A) and was diagnosed with psoriatic arthritis. In the following months, she developed a dry cough and myalgia, and subsequently, in early 2024, progressive dyspnoea and night sweats. Because of the existing prednisolone and TNF-inhibitor treatment for supposed psoriatic arthritis, an infection with <i>pneumocystis jirovecii</i> was suspected. Following a thorough and negative infection screen, the patient was ultimately transferred to the intensive care unit of the Charité with acute respiratory distress syndrome (ARDS) and evaluated for possible lung transplantation (see Figure 1D). Because of progressive respiratory insufficiency, high-dose glucocorticosteroids as well as cyclophosphamide were initiated. The suspected diagnosis was revised to idiopathic inflammatory myopathy (IIM) based on the clinical presentation with arthritis, myalgia with elevated creatine kinase (CK, 939 U/L), scaly exanthema (retrospectively identified as mechanic hands) and rapidly progressive interstitial lung disease (RP-ILD). Immunofluorescence on HEp2 cells revealed a speckled cytoplasmic pattern with a titre of 1:640 (see Figure 1B). Despite repetitive testing of myositis-specific and myositis-associated antibodies with commercial line blots, only anti-Ro52 antibodies were identified. Therefore, after muscle MRI showing patchy oedema and fasciitis, a muscle biopsy of the M. quadriceps was performed. This revealed a histopathological pattern consistent with ASyS: A mild but typical pattern of perifascicular necrosis and atrophy, as well as positive MHC class I and II staining with a perifascicular pattern (particularly for MHC class II) (see Figure 2).</p><p>Combined, the clinical symptoms with a complete clinical triad (Arthritis, Myositis, ILD [<span>2, 3</span>]) and the muscle biopsy consistent with ASyS led to the diagnosis of ASyS [<span>4</span>]. Hence, treatment was expanded to include rituximab (RTX), as a good response to RTX in ASyS had been reported [<span>4, 5</span>]. To search thoroughly for possible autoantibodies in this apparent myositis-specific antibody-negative case, radioimmunoprecipitation was performed at the University of Bath [<span>6</span>] and anti-Ha-antibodies were identified (see Figure 1C). Following RTX therapy, the patient experienced significant improvement of her ILD (see early follow-up CT, Figure 1D). On subsequent outpatient","PeriodicalId":9290,"journal":{"name":"Brain Pathology","volume":"35 5","pages":""},"PeriodicalIF":6.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bpa.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica A. Beck, Christina Mazcko, Sara Belluco, Mireille Bitar, Daniel Brat, Jonathan W. Bush, Rati Chkheidze, Kara N. Corps, Chad Frank, Caterina Giannini, Craig Horbinski, Jason T. Huse, Jennifer W. Koehler, Andrew D. Miller, C. Ryan Miller, M. Gerard O'Sullivan, Joanna J. Phillips, Daniel R. Rissi, Courtney R. Schott, Anat Stemmer-Rachamimov, Stephen Yip, Amy K. LeBlanc
Comparative pathology boards bring together anatomic pathologists with expertise in canine and human histology to identify shared features, including immune or TME components, tumor subtypes, or prognostic tissue biomarkers. This article summarizes feedback to improve future initiatives and enhance the translational relevance of comparative oncology for human patients.